AstraZeneca: EU OKs Lynparza for advanced breast cancer

(CercleFinance.com) - The European Commission has approved AstraZeneca and Merck's drug Lynparza for treating patients with germline BRCA-mutated metastatic breast cancer.


Specifically, the European Commission has approved Lynparza as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations (gBRCAm), and who have human epidermal growth factor receptor 2 (HER2)-negative locally-advanced or metastatic breast cancer.

This is the third indication in Europe for Lynparza, a targeted treatment that blocks DNA damage response in tumours.

Copyright (c) 2019 CercleFinance.com. All rights reserved.